Related Experiment Video
Updated: Jan 2, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
18F-FDG PET/CT Uptake Classification in Lymphoma and Lung Cancer by Using Deep Convolutional Neural Networks
Ludovic Sibille1, Robert Seifert1, Nemanja Avramovic1
1From the Research and Clinical Collaborations, Siemens Medical Solutions USA, 810 Innovation Dr, Knoxville, TN 37932 (L.S., B.S., S.Z.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (R.S., N.A., T.V., M.S.); Cells in Motion (CiM) Cluster of Excellence, University of Münster, Münster, Germany (M.S.); and European Institute for Molecular Imaging, University of Münster, Münster, Germany (R.S., M.S.).
Abstract:
Background Fluorine 18 (18F)-fluorodeoxyglucose (FDG) PET/CT is a routine tool for staging patients with lymphoma and lung cancer. Purpose To evaluate configurations of deep convolutional neural networks (CNNs) to localize and classify uptake patterns of whole-body 18F-FDG PET/CT images in patients with lung cancer and lymphoma. Materials and Methods This was a retrospective analysis of consecutive patients with lung cancer or lymphoma referred to a single center from August 2011 to August 2013. Two nuclear medicine experts manually delineated foci with increased 18F-FDG uptake, specified the anatomic location, and classified these findings as suspicious for tumor or metastasis or nonsuspicious. By using these expert readings as the reference standard, a CNN was developed to detect foci positive for 18F-FDG uptake, predict the anatomic location, and determine the expert classification. Examinations were divided into independent training (60%), validation (20%), and test (20%) subsets. Results This study included 629 patients (mean age, 52.2 years ± 20.4 [standard deviation]; 394 men). There were 302 patients with lung cancer and 327 patients with lymphoma. For the test set (123 patients; 10 782 foci), the CNN areas under the receiver operating characteristic curve (AUCs) for determining hypermetabolic 18F-FDG PET/CT foci that were suspicious for cancer versus nonsuspicious by using the five input features were as follows: CT alone, 0.78 (95% confidence interval [CI]: 0.72, 0.83); 18F-FDG PET alone, 0.97 (95% CI: 0.97, 0.98); 18F-FDG PET/CT, 0.98 (95% CI: 0.97, 0.99); 18F-FDG PET/CT maximum intensity projection (MIP), 0.98 (95% CI: 0.98, 0.99); and 18F-FDG PET/CT MIP atlas, 0.99 (95% CI: 0.98, 1.00). The combination of 18F-FDG PET and CT information improved overall classification accuracy (AUC, 0.975 vs 0.981, respectively; P < .001). Anatomic localization accuracy of the CNN was 2543 of 2639 (96.4%; 95% CI: 95.5%, 97.1%) for body part, 2292 of 2639 (86.9%; 95% CI: 85.3%, 88.5%) for region (ie, organ), and 2149 of 2639 (81.4%; 95% CI: 79.3%-83.5%) for subregion. Conclusion The fully automated anatomic localization and classification of fluorine 18-fluorodeoxyglucose PET uptake patterns in foci suspicious and nonsuspicious for cancer in patients with lung cancer and lymphoma by using a convolutional neural network is feasible and achieves high diagnostic performance when both CT and PET images are used. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Froelich and Salavati in this issue.
More Related Videos
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018